Viking Therapeutics: An Equally Important Catalyst Ahead [Seeking Alpha]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Seeking Alpha
The maintenance study will provide multiple efficacy and tolerability insights on a range of VK2735 regimes, including maintenance dosing with oral VK2735. VKTX maintains a strong cash position ($706M at 2025 year-end), with the company's CFO noting cash burn of $60–90M per quarter going forward. Key risks include competitive readouts (notably LLY's retatrutide), possible fundraising before data, and potential delays in VANQUISH-2 enrollment. wildpixel/iStock via Getty Images Viking Therapeutics ( VKTX ) has already completed enrollment of its VANQUISH-1 study of VK2735 in obesity, and its VANQUISH-2 study in type 2 diabetes/obesity is set to complete enrollment this quarter. Those studies will take 78 weeks This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own op
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
- Why Viking Therapeutics Stock Could Take Off Later This Year [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (VKTX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $102.00 price target on the stock.MarketBeat
- Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics? [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics: Phase 3 Obesity Data Feels Like A Coin Toss (Rating Downgrade) [Seeking Alpha]Seeking Alpha
VKTX
Earnings
- 2/11/26 - Miss
VKTX
Sec Filings
- 3/10/26 - Form 4
- 2/11/26 - Form 10-K
- 2/11/26 - Form 8-K
- VKTX's page on the SEC website